Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL4359248 | 1.00 | PNP (0.62) | PNPMEN1KMT2AALDH1A1MAPT | |
| Guanine SCHEMBL28384883 | 1.00 | PNP (0.62) | PNPMEN1KMT2AALDH1A1MAPT | |
| Guanine SCHEMBL4197782 | 0.88 | PNP (0.53) | PNPMEN1KMT2AALDH1A1MAPT | |
| Thioguanine SCHEMBL2936430 | 0.86 | PNP (0.42) | PNPMEN1KMT2AALDH1A1HPGD | |
| Thioguanine SCHEMBL16028922 | 0.86 | PNP (0.42) | PNPMEN1KMT2AALDH1A1HPGD | |
| Guanine SCHEMBL9861048 | 0.85 | PNP (0.52) | PNP | |
| Hypoxanthine SCHEMBL9538156 | 0.85 | ALDH1A1 (0.53) | PNPMEN1KMT2AALDH1A1MAPT | |
| Isoguanine SCHEMBL11527542 | 0.83 | PNP (0.39) | PNPMEN1KMT2AALDH1A1THRB | |
| Guanine SCHEMBL4198112 | 0.83 | PNP (0.58) | PNPMEN1KMT2AALDH1A1MAPT | |
| Cytidine SCHEMBL3129099 | 0.81 | LMNA (0.67) | PNPALDH1A1MAPTTHRBGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3430031-B1 | PEPTIDES WITH ANTI-CANCER ACTIVITY | IDP DISCOVERY PHARMA S L (ES) | 2021-10-20 | — | — | EP | claimed |
| US-20120258126-A1 | Molecular Vaccines for Infectious Disease | DAKO DENMARK A/S (DK) | 2012-10-11 | — | — | US | claimed |
| US-20110293565-A1 | NOVEL SYNTHETIC AGONISTS OF TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | claimed |
| EP-2337795-A2 | MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING | Dako Denmark A/S (DK) | 2011-06-29 | — | — | EP | claimed |
| WO-2010088395-A2 | NOVEL SYNTHETIC AGONISTS OF TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010037402-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | claimed |
| WO-2010037395-A2 | MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | claimed |
| EP-1296714-B1 | Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. | UNIV IOWA RES FOUND (US) | 2009-08-26 | — | — | EP | claimed |
| US-20080206265-A1 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | IDERA PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | claimed |
| CN-1939541-A | Immunostimulatory nucleic acids | UNIV IOWA RES FOUND (US) | 2007-04-04 | — | — | CN | claimed |
| WO-2004103301-A2 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | HYBRIDON, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | claimed |
| WO-2004012746-A2 | NEW USES FOR INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | claimed |
| EP-1296714-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2003-04-02 | — | — | EP | claimed |
| US-20030026801-A1 | Methods for enhancing antibody-induced cell lysis and treating cancer | PFIZER INC. | 2003-02-06 | — | — | US | claimed |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2002-12-19 | — | — | US | claimed |
| US-20020156033-A1 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2002-10-24 | — | — | US | claimed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | claimed |
| WO-2001097843-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2000040269-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASED TISSUES | LEE CLARENCE C (US) | 2000-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | PNP, GALE, MTAP | PNP 1/4885MEN1 2061/4885KMT2A 3281/4885 |
| US-20110293565-A1 | NOVEL SYNTHETIC AGONISTS OF TLR9 | TLR9, TLR3, TLR7 | PNP 2131/4885MEN1 4580/4885KMT2A 1919/4885 |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | IMPDH1, IMPDH2, IMPA1 | PNP 15/4885MEN1 2144/4885KMT2A 2246/4885 |
| US-20080206265-A1 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | CD74, CD47, DCLRE1B | PNP 2712/4885MEN1 3480/4885KMT2A 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.